Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
ACTIVE_NOT_RECRUITING
Status
Conditions
- Chronic Lymphocytic Leukemia
- Follicular Lymphoma
- Lymphoplasmacytic Lymphoma
- Mantle Cell Lymphoma
- Marginal Zone Lymphoma
- Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
- Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
- Small Lymphocytic Lymphoma
- Waldenstrom Macroglobulinemia
Interventions
- DRUG: Ixazomib Citrate
- OTHER: Laboratory Biomarker Analysis
- BIOLOGICAL: Rituximab
Sponsor
University of Washington
Collaborators